Inhibitors | Comment | Organism | Structure |
---|---|---|---|
bortezomib | ONX0912 acts synergistically with bortezomib | Homo sapiens | |
ONX0912 | a selective, irreversible inhibitor of the chymotrypsin-like activity of constitutive proteasome 20S and immunoproteasome 20S. ONX0912 exerts toxicity in Waldenstroem macroglobulinemia cells, by reducing bone marrow-derived interleukin-6 and insulin-like growth factor 1 secretion, thus inhibiting BM-induced p-Akt and phosphorylated extracellular signal-related kinase activation in Waldenstroem macroglobulinemia cells, overview. ONX0912 acts synergistically with bortezomib | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
BCWM.1 cell | - |
Homo sapiens | - |
bone marrow | primary Waldenstroem macroglobulinemia cells | Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
N-succinyl-LLVY-7-amido-4-methylcoumarin + H2O | chymotrypsin-like proteasome activity | Homo sapiens | N-succinyl-LLVY + 7-amino-4-methylcoumarin | - |
? |
Synonyms | Comment | Organism |
---|---|---|
c20S | - |
Homo sapiens |
constitutive proteasome 20S | - |
Homo sapiens |
i20S | - |
Homo sapiens |
immunoproteasome 20S | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
additional information | primary Waldenstroem macroglobulinemia cells express higher level of immunoproteasome 20S compared with constitutive proteasome 20S. Selective inhibition of the chymotrypsin-like activity of constitutive proteasome 20S and immunoproteasome 20S represents a sufficient and successful strategy to induce antineoplastic effect in hematologic tumors | Homo sapiens |